接受洛匹那韦/利托那韦和阿扎那韦/利托那韦为基础的抗逆转录病毒药物的HIV感染患者高脂血症严重程度的比较评估
Comparative Assessment of the Magnitude of Hyperlipidemia in HIV-Infected Patients Receiving Lopinavir/r- and Atazanavir/r-Based Antiretroviral Drugs.
作者信息
Muya Esther, Kamuhabwa Appolinary
机构信息
1 Department of Clinical Pharmacy and Pharmacology, School of Pharmacy, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
出版信息
J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958219841908. doi: 10.1177/2325958219841908.
Abstract
OBJECTIVE
To assess prevalence of hyperlipidemia in patients receiving lopinavir boosted with ritonavir (LPV/r) and atazanavir boosted with ritonavir (ATV/r) antiretroviral drugs.
METHODS
HIV-infected patients (300) were recruited in the study between December 2015 and April 2016. Lipid profile including triglycerides (TG), high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol (LDL-C) were assessed.
RESULTS
Prevalence of derangement in TG was 71.0% in patients using LPV/r compared to 44% in those using ATV/r ( P = .01). Use of LPV/r was independently associated with increased total cholesterol (TC; P = .001) and TG ( P = .0003). Females had raised levels of TC compared to males ( P = .00008). Body mass index of ≥ 25 kg/m was also associated with raised TC ( P = .002) and LDL-C ( P = .006).
CONCLUSION
LPV/r was significantly associated with lipid derangements, indicating the need to regularly monitor lipid profile in patients using LPV/r.
摘要
目的
评估接受洛匹那韦利托那韦（LPV/r）和阿扎那韦利托那韦（ATV/r）抗逆转录病毒药物治疗的患者中高脂血症的患病率。
方法
2015年12月至2016年4月期间招募了300名HIV感染患者进行该研究。评估了包括甘油三酯（TG）、高密度脂蛋白胆固醇和低密度脂蛋白胆固醇（LDL-C）在内的血脂谱。
结果
使用LPV/r的患者中TG紊乱的患病率为71.0%，而使用ATV/r的患者中这一比例为44%（P = 0.01）。使用LPV/r与总胆固醇（TC；P = 0.001）和TG（P = 0.0003）升高独立相关。女性的TC水平高于男性（P = 0.00008）。体重指数≥25 kg/m²也与TC升高（P = 0.002）和LDL-C升高（P = 0.006）相关。
结论
LPV/r与脂质紊乱显著相关，这表明需要对使用LPV/r的患者定期监测血脂谱。
相似文献
1
Comparative Assessment of the Magnitude of Hyperlipidemia in HIV-Infected Patients Receiving Lopinavir/r- and Atazanavir/r-Based Antiretroviral Drugs.接受洛匹那韦/利托那韦和阿扎那韦/利托那韦为基础的抗逆转录病毒药物的HIV感染患者高脂血症严重程度的比较评估
J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958219841908. doi: 10.1177/2325958219841908.
2
Impact of switching from lopinavir/ritonavir to boosted and un-boosted atazanavir on glucose metabolism: the ATAzanavir & GLUcose metabolism (ATAGLU) study.从洛匹那韦/利托那韦转换为增强和非增强型阿扎那韦对糖代谢的影响：阿扎那韦与糖代谢（ATAGLU）研究
Int J STD AIDS. 2016 Jul;27(8):638-43. doi: 10.1177/0956462415590724. Epub 2015 Jun 10.
3
Impact of Lopinavir/Ritonavir and Efavirenz-Based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-Naïve Patients in Beijing: A Retrospective Study.洛匹那韦/利托那韦和依非韦伦为基础的抗逆转录病毒疗法对北京初治中国HIV/AIDS患者血脂谱的影响：一项回顾性研究
Curr HIV Res. 2019;17(5):324-334. doi: 10.2174/1570162X17666191025115508.
4
Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study.在使用较老的蛋白酶抑制剂治疗的围生期感染 HIV 的儿童和青少年中，换用增效后的阿扎那韦或达芦那韦后血脂改善：儿科 HIV/AIDS 队列研究的结果。
HIV Med. 2018 Mar;19(3):175-183. doi: 10.1111/hiv.12566. Epub 2017 Nov 21.
5
An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir.在乌干达一家城市诊所进行的一项观察性研究，比较了将一线抗逆转录病毒治疗方案转换为含有利托那韦增强型阿扎那韦或利托那韦增强型洛匹那韦的二线方案的患者的病毒学结局。
BMC Infect Dis. 2019 Mar 25;19(1):280. doi: 10.1186/s12879-019-3907-5.
6
Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients.从洛匹那韦/利托那韦转换为阿扎那韦/利托那韦对HIV感染患者肌肉葡萄糖摄取和内脏脂肪的影响。
AIDS. 2009 Jul 17;23(11):1349-57. doi: 10.1097/QAD.0b013e32832ba904.
7
Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings.资源有限环境下接受洛匹那韦/利托那韦单一疗法的HIV感染患者的高脂血症
Antivir Ther. 2017;22(3):205-213. doi: 10.3851/IMP3101. Epub 2016 Oct 14.
8
Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection.初治HIV-1感染患者中，阿扎那韦/利托那韦与洛匹那韦/利托那韦分别联合替诺福韦/恩曲他滨时身体成分变化的比较。
Clin Drug Investig. 2014 Apr;34(4):287-96. doi: 10.1007/s40261-014-0175-4.
9
Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART.对接受抑制性高效抗逆转录病毒治疗（HAART）不耐受的HIV感染患者换用依曲韦林后的降脂效果及疗效。
HIV Clin Trials. 2013 Jan-Feb;14(1):1-9. doi: 10.1310/hct1401-1.
10
Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.2011 年英国初治和经治的抗逆转录病毒治疗（ART）患者中洛匹那韦/利托那韦（LPV/r）和阿扎那韦/利托那韦（ATV+RTV）方案的经济学和与健康相关的生活质量（HRQoL）比较。
J Med Econ. 2012;15(4):796-806. doi: 10.3111/13696998.2012.691927. Epub 2012 Jun 7.
引用本文的文献
1
Lack of Association of Vascular Risk Factors with HIV-Associated Neurocognitive Disorders in cART-Treated Adults Aged ≥ 50 Years in Tanzania.在坦桑尼亚≥50 岁接受 cART 治疗的成年人中，血管危险因素与 HIV 相关神经认知障碍之间缺乏关联。
Viruses. 2024 May 22;16(6):819. doi: 10.3390/v16060819.
2
Low incidence of advanced neurological burden but high incidence of age-related conditions that are dementia risk factors in aging people living with HIV: a data-linkage 10-year follow-up study.HIV 感染者中，年龄相关疾病的发病率高，但导致认知障碍的高级神经病变发病率低：一项数据链接 10 年随访研究。
J Neurovirol. 2023 Apr;29(2):141-155. doi: 10.1007/s13365-022-01104-0. Epub 2022 Dec 12.
3
Effectors of Hyperlipidemia among HIV/AIDS patients with second-line antiretroviral therapy based on register data.基于登记数据的接受二线抗逆转录病毒治疗的艾滋病毒/艾滋病患者高脂血症的影响因素
Curr HIV Res. 2022 Aug 5;20(5):373-9. doi: 10.2174/1570162X20666220805103411.
4
Prevalence of dyslipidaemia among HIV-infected patients receiving combination antiretroviral therapy in North Shewa, Ethiopia.埃塞俄比亚北谢瓦接受联合抗逆转录病毒治疗的艾滋病毒感染患者血脂异常的患病率。
PLoS One. 2021 Apr 27;16(4):e0250328. doi: 10.1371/journal.pone.0250328. eCollection 2021.
本文引用的文献
1
Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings.资源有限环境下接受洛匹那韦/利托那韦单一疗法的HIV感染患者的高脂血症
Antivir Ther. 2017;22(3):205-213. doi: 10.3851/IMP3101. Epub 2016 Oct 14.
2
Lipid Profile in HIV-Infected Patients Using First-Line Antiretroviral Drugs.使用一线抗逆转录病毒药物的HIV感染患者的血脂谱
J Int Assoc Provid AIDS Care. 2016 Mar-Apr;15(2):164-71. doi: 10.1177/2325957415614642. Epub 2015 Oct 29.
3
Highly active antiretroviral therapy and dyslipidemia in people living with HIV/AIDS in Fako Division, South West Region of Cameroon.喀麦隆西南地区法科分区感染艾滋病毒/艾滋病者的高效抗逆转录病毒疗法与血脂异常
BMC Cardiovasc Disord. 2015 Aug 28;15:95. doi: 10.1186/s12872-015-0090-5.
4
Managing dyslipidemia in HIV/AIDS patients: challenges and solutions.管理艾滋病毒/艾滋病患者的血脂异常：挑战与解决方案。
HIV AIDS (Auckl). 2014 Dec 17;7:1-10. doi: 10.2147/HIV.S46028. eCollection 2015.
5
Magnitude and risk factors of non-communicable diseases among people living with HIV in Tanzania: a cross sectional study from Mbeya and Dar es Salaam regions.坦桑尼亚艾滋病毒感染者中非传染性疾病的严重程度和风险因素：一项来自姆贝亚和达累斯萨拉姆地区的横断面研究。
BMC Public Health. 2014 Sep 2;14:904. doi: 10.1186/1471-2458-14-904.
6
Changes in Lipid Profiles and Other Biochemical Parameters in HIV-1 Infected Patients Newly Commenced on HAART Regimen.开始接受高效抗逆转录病毒治疗（HAART）方案的新确诊HIV-1感染患者的血脂谱及其他生化参数变化
Infect Dis (Auckl). 2013 Mar 6;6:7-14. doi: 10.4137/IDRT.S10044. eCollection 2013.
7
Fat depots, free fatty acids, and dyslipidemia.脂肪组织、游离脂肪酸与血脂异常。
Nutrients. 2013 Feb 7;5(2):498-508. doi: 10.3390/nu5020498.
8
Prevalence of dyslipidemia among HIV-infected patients using first-line highly active antiretroviral therapy in Southern Ethiopia: a cross-sectional comparative group study.在埃塞俄比亚南部，使用一线高效抗逆转录病毒疗法的 HIV 感染患者中血脂异常的流行情况：一项横断面对比组研究。
AIDS Res Ther. 2012 Oct 25;9(1):31. doi: 10.1186/1742-6405-9-31.
9
Cancer and the 'other' noncommunicable chronic diseases in older people living with HIV/AIDS in resource-limited settings: a challenge to success.在资源有限的环境下，老年 HIV/AIDS 患者中的癌症和其他非传染性慢性疾病：成功的挑战。
AIDS. 2012 Jul 31;26 Suppl 1:S65-75. doi: 10.1097/QAD.0b013e328355ab72.
10
Integration of HIV and noncommunicable diseases in health care delivery in low- and middle-income countries.低收入和中等收入国家医疗服务中艾滋病病毒与非传染性疾病的整合
Prev Chronic Dis. 2012;9:E93. doi: 10.5888/pcd9.110331. Epub 2012 May 3.
Zotero 插件